Anzeige
Erschienen in:
02.11.2015 | Original article
Ticagrelor vs. clopidogrel in non-ST-elevation acute coronary syndromes
Erschienen in: Herz | Ausgabe 3/2016
Einloggen, um Zugang zu erhaltenAbstract
Aim
The aim of this study was to evaluate the bradyarrhythmic events associated with ticagrelor combination therapy in the management of patients presenting with non-ST-segment elevation myocardial infarction (NSTEMI).
Patients and methods
The study comprised 300 patients with NSTEMI who were treated via percutaneous coronary intervention (PCI). Patients were randomly assigned to two groups: the clopidogrel group (initial dose of 300 mg and then maintenance dose of 75 mg once daily, n = 151) and the ticagrelor group (initial dose of 180 mg and then maintenance dose of 90 mg twice daily, n = 149). All patients were followed up in the outpatient clinic. Follow-up included 12-lead electrocardiography and 24-h Holter monitoring performed 1, 6, and 12 months after the revascularization procedure.
Results
Of the 300 patients, 112 patients (36.7 %) had a decrease in heart rate at the 12-month follow-up. Of these, 80 patients were in the ticagrelor group (53.3 %) vs. 32 patients in the clopidogrel group (24.7 %; p < 0.05). However, the difference was not statistically significant at the 1-month and 6-month follow-up visits. After adjusting for potential confounders, the reduction in heart rate with ticagrelor combination therapy remained independently associated with a reduced risk of major adverse cardiovascular events (hazard ratio, 2.1; 95 % CI, 1.90–2.23), while ticagrelor therapy reduced the risk to a level equivalent to that of patients in the clopidogrel group.
Conclusion
Ticagrelor can lower the resting heart rate of patients and cause bradyarrhythmias in the 12th month after PCI.